ema

News

Autolus closes on EU okay for leukaemia cell therapy

The CHMP backed approval of Autolus' leukaemia CAR-T Aucatzyl, as well as drugs from GSK, Roche, SpringWorks, and others, at its May meeting.

Market Access

pharmaphorum podcast Episode 178a - Sandra Anderson and Chris Williams, Cencora

The value of a partner, globally and locally

A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face

News

Dyvyzat box, bottle, and oral delivery mechanism.

Italfarmaco closes on EU okay for Duchenne drug

Italfarmaco's oral HDAC inhibitor Duvyzat has been recommended for approval in the EU as a treatment for Duchenne muscular dystrophy (DMD).

Digital

Leveraging data, digitalisation, and artificial intelligence...

In an era marked by rapid technological advancements and evolving healthcare needs, the European Medicines Agencies Network Strategy 2028 stands as a key

News

Surgeon with surgical gloves on holding a brain scan

Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla

The CHMP has advised against EU approval of Eli Lilly's Alzheimer's drug Kisunla, potentially handing an advantage to Eisai/Biogen's rival drug.

News

EMA panel endorses AI for MASH clinical trials

PathAI's artificial intelligence tool for diagnosing MASH has become the first to be recommended under the EMA's Qualification Opinion framework.

Autolus closes on EU okay for leukaemia cell therapy

The value of a partner, globally and locally

Italfarmaco closes on EU okay for Duchenne drug

Leveraging data, digitalisation, and artificial intelligence...

Lilly to appeal after CHMP rejects Alzheimer's drug Kisunla

EMA panel endorses AI for MASH clinical trials

FDA points to liver injury with Amgen's Tavneos

Using AI-driven synthetic personas to take your insights fur...

ema

Editor's Picks